Related Experiment Video
Updated: Oct 3, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
ALIMTA (pemetrexed disodium, LY231514, MTA): clinical experience in non-small cell lung cancer
1Department of Medicine, Institut Gustave-Roussy, Villejuif, France. silvia.novello@it.tiscali.com
Abstract:
ALIMTA is a novel, multi-targeted antifolate which inhibits several enzymes of the folate pathways and it has demonstrated a broad spectrum of clinical activity in multiple tumor types, including colorectal, breast, non-small cell lung cancer (NSCLC), pancreatic, head and neck, bladder and cervical cancers. ALIMTA has been tested in different patient populations, including those who have received no prior chemotherapy, those who have relapsed following prior platinum-containing therapy, and those who have relapsed following prior chemotherapy without platinum. In every group was demonstrated an activity comparable to currently used new drugs. ALIMTA was also studied in association with cisplatin in chemotherapy-naive patients and the overall response rate is comparable to other current combination regimens. From December 1999, an amendment has been made to all studies to add vitamin supplementation to reduce toxicity and early indications are that the frequency of serious toxicities resulting from ALIMTA treatment has been reduced. On the basis of the results of the studies reviewed, it is clear that ALIMTA is emerging as a new drug in the management of NSCLC.
Insights
Pemetrexed (ALIMTA) is a novel antifolate drug showing broad clinical activity across various cancers, including non-small cell lung cancer (NSCLC). Vitamin supplementation has shown promise in reducing its toxicity.
Area of Science:
- Oncology
- Pharmacology
- Drug Development
Background:
- Pemetrexed (ALIMTA) is a novel antifolate agent targeting multiple enzymes in folate pathways.
- It exhibits a broad spectrum of clinical activity in various cancer types.
Purpose of the Study:
- To evaluate the clinical activity and toxicity of Pemetrexed (ALIMTA) in diverse patient populations.
- To assess Pemetrexed (ALIMTA) in combination with cisplatin.
- To investigate the impact of vitamin supplementation on Pemetrexed (ALIMTA) toxicity.
Main Methods:
- Clinical trials involving patients with colorectal, breast, NSCLC, pancreatic, head and neck, bladder, and cervical cancers.
- Testing in chemotherapy-naive, relapsed platinum-treated, and relapsed non-platinum-treated populations.
- Combination therapy with cisplatin in chemotherapy-naive patients.
- Addition of vitamin supplementation to reduce toxicity.
Main Results:
- Pemetrexed (ALIMTA) demonstrated activity comparable to existing drugs across all tested patient groups.
- Combination therapy with cisplatin showed a comparable overall response rate to other regimens.
- Early data indicate reduced serious toxicities with vitamin supplementation.
Conclusions:
- Pemetrexed (ALIMTA) is an active agent in multiple cancer types, including NSCLC.
- Vitamin supplementation appears to mitigate Pemetrexed (ALIMTA) associated toxicities.
- Pemetrexed (ALIMTA) is emerging as a significant therapeutic option for NSCLC management.